clinical trial · NCT05262010
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
National Vaccine and Serum Institute, China·phase3·recruiting·n = 13,500
HPV InfectioNHPV-Related Carcinoma11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)placebo
brief summary
A total of 13500 Chinese women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 35-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1. All subjects enrolled in the upper arm deltoid muscle were injected with 3 doses of test vaccine or placebo according to the 0, 2, and 6 months immunization program.
started
Jun 4, 2022
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Jan 16, 2026
official title
A Multicenter Randomized, Blinded, Placebo-controlled Phase III Clinical Trial Evaluating the Protective Efficacy, Safety and Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol